IP Library › Granted Patent US 12,551,491
Granted Patent B1
US 12,551,491 · App. 19/278,636 · Granted Feb 17, 2026

Dosage regimens for benzgalantamine

Inventors: Michael McFadden (Frisco, TX); Denis G. Kay (Stanhope, CA)
Assignee: Alpha Cognition Inc.
A61K31/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,551,491
App. No.
19/278,636
Granted
Feb 17, 2026
Kind
B1
Abstract

A method of effectively reducing the pharmaceutical load of galantamine relative to oral administration of galantamine or a method of effectively administering galantamine in a subject in need of galantamine therapy for the treatment of mild to moderate dementia of the Alzheimer's type, the methods including orally administering a dosage form of benzgalantamine gluconate according to the following dosage regime: administering a starting dosage of 5 mg benzgalantamine gluconate, twice daily, for a minimum of four weeks.

Claims (23)

1 . A method of effectively reducing the pharmaceutical load of galantamine relative to oral administration of galantamine in a subject in need of galantamine therapy for the treatment of mild to moderate dementia of the Alzheimer's type, the method comprising orally administering a dosage form of benzgalantamine gluconate according to the following dosage regime:

administering a starting dosage of 5 mg benzgalantamine gluconate, twice daily, for a minimum of four weeks.

2 . The method according to claim 1 , further comprising administering a maintenance dosage of 10 mg benzgalantamine gluconate, twice daily, after the starting dosage has been administered for the minimum of four weeks.

3 . The method according to claim 2 , wherein the 10 mg of benzgalantamine gluconate is administered for at least four weeks.

4 . The method according to claim 3 , further comprising administering a maximum dosage of 15 mg benzgalantamine gluconate, twice daily after administering the 10 mg benzgalantamine gluconate.

5 . The method according to claim 1 , wherein a steady state of galantamine is achieved within one week.

6 . The method according to claim 1 , wherein the dosage form is a tablet.

7 . The method according to claim 5 , wherein the dosage form is a delayed release tablet.

8 . The method according to claim 5 , wherein the dosage form comprises calcium silicate.

9 . The method according to claim 7 , wherein the dosage form comprises at least one of colloidal silicon dioxide, mannitol, and methacrylic acid.

10 . The method according to claim 6 , wherein the delayed release tablet comprises an enteric coating comprising methacrylic acid.

11 . The method according to claim 10 , wherein the enteric coating comprises a methacrylic acid-ethyl acrylate copolymer.

12 . A method of effectively administering galantamine to a subject in need of treatment for mild to moderate dementia of the Alzheimer's type, the method comprising orally administering a dosage form of benzgalantamine gluconate according to the following dosage regime:

administering a starting dosage of 5 mg benzgalantamine gluconate, twice daily, for a minimum of four weeks.

13 . The method according to claim 12 , further comprising administering a dosage of 10 mg benzgalantamine gluconate, twice daily, after the starting dosage has been administered for the minimum of four weeks.

14 . The method according to claim 13 , further comprising administering a maximum dosage of 15 mg benzgalantamine gluconate, twice daily.

15 . The method according to claim 12 , wherein a steady state of galantamine is achieved within one week.

16 . The method according to claim 12 , wherein the dosage form is a tablet.

17 . The method according to claim 16 , wherein the dosage form is a delayed release tablet.

18 . The method according to claim 12 , wherein the dosage form comprises calcium silicate.

19 . The method according to claim 12 , wherein the dosage form comprises at least one of colloidal silicon dioxide, mannitol, and methacrylic acid.

20 . The method according to claim 17 , wherein the delayed release tablet comprises an enteric coating comprising methacrylic acid.

21 . The method according to claim 18 , wherein the enteric coating comprises a methacrylic acid-ethyl acrylate copolymer.

Assignments (2)
CHANGE OF ADDRESS Recorded Jul 10, 2026
From: ALPHA COGNITION INC.
To: ALPHA COGNITION INC.
Reel/Frame 075996/0040 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2025
From: MCFADDEN, MICHAEL; KAY, DENIS G.
To: ALPHA COGNITION INC.
Reel/Frame 072058/0900 →
References Cited (35)
US 6150359A · Barvian · 2000 [cited by examiner]
US 6316439B1 · Kosley, Jr · 2001 [cited by examiner]
US 6323195B1 · Kosley, Jr · 2001 [cited by examiner]
US 6323196B1 · Kosley, Jr · 2001 [cited by examiner]
US 9763953B2 · Maelicke · 2017 [cited by applicant]
US 10265325B2 · Maelicke · 2019 [cited by applicant]
US 11077119B2 · Maelicke · 2021 [cited by applicant]
US 11795176B2 · Sancilio · 2023 [cited by applicant]
US 12157743B2 · Sancilio · 2024 [cited by applicant]
US 12208167B1 · McFadden · 2025 [cited by examiner]
US 20030060423A1 · Plata-Salaman · 2003 [cited by applicant]
US 20060034937A1 · Patel · 2006 [cited by applicant]
US 20210322437A1 · Maelicke · 2021 [cited by applicant]
US 20250248941A1 · McFadden et al. · 2025 [cited by applicant]
WO WO2007039138A1 · 2007 [cited by applicant]
WO WO2009127218A1 · 2009 [cited by examiner]
WO WO2014016430A1 · 2014 [cited by examiner]
WO WO2022025785A1 · 2022 [cited by applicant]
WO WO2022150917A1 · 2022 [cited by applicant]
WO WO2022236396A1 · 2022 [cited by applicant]
WO WO2023092231A1 · 2023 [cited by applicant]
WO WO2024239120A1 · 2024 [cited by applicant]
WO WO2025166455A1 · 2025 [cited by applicant]
Battacharya et al., “Nasal Application of the Galantamine Pro-drug Memogain Slows Down Plaque Deposition and Ameliorates Behavior in 5X Familial Alzheimer's Disease Mice”, Journal of Alzheimer's disease, 2015, 46: 123-1… [cited by applicant]
Bakker et al., “Safety, pharmacokinetics, and pharmacodynamics of Gln-1062, a prodrug of galantamine”, Alzheimer's Dementia, 2020, 6(1): e12093 (in 10 pages). [cited by applicant]
Baakman et al., “First in human study with a prodrug of galantamine: Improved benefit-risk ratio?”, Alzheimer's & Dementia, Jan. 2, 20160; 2(1): 13-22. [cited by applicant]
Kay et al., “ALPHA-1062 Reduces Phospho-Tau Deposition, is Neuroprotective and Enhances Restoration of Sensory, Motor and Cognitive Performance in a Preclinical Model of Moderate Traumatic Brain Injury”, Military Health… [cited by applicant]
Kay DG et al., “A Quantitative-EEG Assessment of Alpha-1062, a Novel Pro-Drug of Galantamine for the Treatment of Mild to Moderate Dementia Associated with Alzheimer's Disease”, Alzheimer's & Dementia 2022; 18(Suppl. 10… [cited by applicant]
Kay DG et al., “Multiple Ascending Dose Study with A Prodrug of Galantamine: Evidence of DiminishedSide Effects.”, The Journal of Prevention of Alzheimer's Disease—JPAD @ vol. 3, Supplement 1, 2016, P3-26. [cited by applicant]
Kay DG et al., “Multiple Ascending Dose Study with A Prodrug of Galantamine: A Pharmaco-EEG Analysis With Evidence of Positive Effects On Cognition”, The Journal of Prevention of Alzheimer's Disease—JPAD@ vol. 4, No. 4,… [cited by applicant]
Maelicke et al., “Memogain is a Galantamine Pro-drug having Dramatically Reduced Adverse Effects and Enhanced Efficacy”. Journal of Molecular Neuroscience, Jan. 1, 2010, vol. 40, No. 1-2135-137. [cited by applicant]
Sornsuvit, C et al. (2020) “Pharmacokinetics of 8 mg galantamine hydrobromide prolonged-release capsules under fed and fasting conditions,” The Journal of Pharmaceutical Sciences: vol. 44(1): 23-29. [cited by applicant]
Van Kampen et al.“Neurogenic effects of the galantamine prodrug, GLN-1062a”, Alzheimer's & Dementia, 2012, P2-369. [cited by applicant]
Van Kampen et al., “Memogain Regulates Tau Phosphorylation In An Immunotoxin Model Of Cholinergic Cell Loss”, Alzheimer's & Dementia 2018, P4-022. [cited by applicant]
Alpha Cognition Inc.—Drug Label Information: Zunveyl, benzgalantamine tablet, delayed release, Feb. 18, 2025, (34 pages). [cited by applicant]